Glucose-lowering drug use in migrants and native Danes with type 2 diabetes: Disparities in combination therapy and drug types.
Humans
Cross-Sectional Studies
Diabetes Mellitus, Type 2
/ drug therapy
Dipeptidyl-Peptidase IV Inhibitors
/ therapeutic use
Drug Therapy, Combination
Glucagon-Like Peptide-1 Receptor
/ therapeutic use
Glucose
/ therapeutic use
Hypoglycemic Agents
/ therapeutic use
Sodium-Glucose Transporter 2 Inhibitors
/ therapeutic use
Transients and Migrants
Healthcare Disparities
GLP-1 analogue
antidiabetic drug
pharmacoepidemiology
population study
primary care
type 2 diabetes
Journal
Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
revised:
12
07
2023
received:
16
03
2023
accepted:
14
07
2023
medline:
4
10
2023
pubmed:
8
8
2023
entrez:
8
8
2023
Statut:
ppublish
Résumé
To examine disparities in glucose-lowering drug (GLD) usage between migrants and native Danes with type 2 diabetes (T2D). In a nationwide, register-based cross-sectional study of 253 364 individuals with prevalent T2D on December 31, 2018, we examined user prevalence during 2019 of (i) GLD combination therapies and (ii) individual GLD types. Migrants were grouped by origin (Middle East, Europe, Turkey, Former Yugoslavia, Pakistan, Sri Lanka, Somalia, Vietnam), and relative risk (RR) versus native Danes was computed using robust Poisson regression to adjust for clinical and socioeconomic characteristics. In 2019, 34.7% of native Danes received combination therapy, and prevalence was lower in most migrant groups (RR from 0.78, 95% confidence interval CI 0.71-0.85 [Somalia group] to 1.00, 95% CI 0.97-1.04 [former Yugoslavia group]). Among native Danes, the most widely used oral GLD was metformin (used by 62.1%), followed by dipeptidyl peptidase-4 inhibitors (13.3%), sodium-glucose cotransporter-2 inhibitors (11.9%) and sulphonylureas (5.2%), and user prevalence was higher in most migrant groups (RR for use of any oral GLD: 0.99, 95% CI 0.97-1.01 [Europe group] to 1.09, 95% CI 1.06-1.11 [Sri Lanka group]). Furthermore, 18.7% of native Danes used insulins and 13.3% used glucagon-like peptide-1 receptor agonists (GLP-1RAs), but use was less prevalent in migrants (RR for insulins: 0.66, 95% CI 0.62-0.71 [Sri Lanka group] to 0.94, 95% CI 0.89-0.99 [Europe group]; RR for GLP-1RAs: 0.29, 95% CI 0.22-0.39 [Somalia group] to 0.95, 95% CI 0.89-1.01 [Europe group]). Disparities in GLD types and combination therapy were evident between migrants and native Danes. Migrants were more likely to use oral GLDs and less likely to use injection-based GLDs, particularly GLP-1RAs, which may contribute to complication risk and mortality among this group.
Substances chimiques
Dipeptidyl-Peptidase IV Inhibitors
0
Glucagon-Like Peptide-1 Receptor
0
Glucose
IY9XDZ35W2
Hypoglycemic Agents
0
Sodium-Glucose Transporter 2 Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3307-3316Informations de copyright
© 2023 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
Références
Bonnet F, Chen H, Cooper A, et al. What are the factors associated with long-term glycaemic control in patients with type 2 diabetes and elevated glycated haemoglobin (≥7.0%) at initiation of second-line therapy? Results from the DISCOVER study. Diabetes Obes Metab. 2021;23(10):2336-2343. doi:10.1111/dom.14476
Lee CMY, Woodward M, Colagiuri S. Triple therapy combinations for the treatment of type 2 diabetes - a network meta-analysis. Diabetes Res Clin Pract. 2016;116:149-158. doi:10.1016/j.diabres.2016.04.037
Kim K, Unni S, Brixner DI, et al. Longitudinal changes in glycated haemoglobin following treatment intensification after inadequate response to two oral antidiabetic agents in patients with type 2 diabetes. Diabetes Obes Metab. 2019;21(7):1725-1733. doi:10.1111/dom.13694
Kristensen JK, Bak JF, Wittrup I, Lauritzen T. Diabetes prevalence and quality of diabetes care among Lebanese or Turkish immigrants compared to a native Danish population. Prim Care Diabetes. 2007;1(3):159-165. doi:10.1016/j.pcd.2007.07.007
Holm AL, Andersen GS, Jorgensen ME, Diderichsen F. Is the rule of halves framework relevant for diabetes care in Copenhagen today? A register-based cross-sectional study. BMJ Open. 2018;8(11):e023211. doi:10.1136/bmjopen-2018-023211
Tran AT, Diep LM, Cooper JG, et al. Quality of care for patients with type 2 diabetes in general practice according to patients' ethnic background: a cross-sectional study from Oslo, Norway. BMC Health Services Res. 2010;10(1):145. doi:10.1186/1472-6963-10-145
Negandhi PH, Ghouri N, Colhoun HM, et al. Ethnic differences in glycaemic control in people with type 2 diabetes mellitus living in Scotland. PloS One. 2013;8(12):e83292. doi:10.1371/journal.pone.0083292
Rawshani A, Svensson A-M, Rosengren A, Zethelius B, Eliasson B, Gudbjörnsdottir S. Impact of ethnicity on progress of glycaemic control in 131,935 newly diagnosed patients with type 2 diabetes: a nationwide observational study from the Swedish National Diabetes Register. BMJ Open. 2015;5(6):e007599. doi:10.1136/bmjopen-2015-007599
Mathur R, Farmer RE, Eastwood SV, Chaturvedi N, Douglas I, Smeeth L. Ethnic disparities in initiation and intensification of diabetes treatment in adults with type 2 diabetes in the UK, 1990-2017: a cohort study. PLoS Med. 2020;17(5):e1003106. doi:10.1371/journal.pmed.1003106
Marchesini G, Bernardi D, Miccoli R, et al. Under-treatment of migrants with diabetes in a universalistic health care system: the ARNO observatory. Nutr Metab Cardiovasc Dis. 2014;24(4):393-399. doi:10.1016/j.numecd.2013.09.012
Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-1844. doi:10.1056/NEJMoa1607141
Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-322. doi:10.1056/NEJMoa1603827
Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. The Lancet. 2019;394(10193):121-130. doi:10.1016/S0140-6736(19)31149-3
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128. doi:10.1056/NEJMoa1504720
Mahaffey KW, Neal B, Perkovic V, et al. Canagliflozin for primary and secondary prevention of cardiovascular events. Circulation. 2018;137(4):323-334. doi:10.1161/CIRCULATIONAHA.117.032038
Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2018;380(4):347-357. doi:10.1056/NEJMoa1812389
Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD). Diabetes Care. 2022;45(11):2753-2786. doi:10.2337/dci22-0034
Farmakologisk behandling af hyperglykaemi. 2022 Available from https://vejledninger.dsam.dk/fbv-t2dm/?mode=visKapitel&cid=1487&gotoChapter=1490
Chaturvedi N, Jarrett J, Shipley MJ, Fuller JH. Socioeconomic gradient in morbidity and mortality in people with diabetes: cohort study findings from the Whitehall study and the WHO multinational study of vascular disease in diabetes. BMJ (Clin Res Ed). 1998;316(7125):100-105. doi:10.1136/bmj.316.7125.100
Slåtsve KB, Claudi T, Lappegård KT, et al. Level of education is associated with coronary heart disease and chronic kidney disease in individuals with type 2 diabetes: a population-based study. BMJ Open Diabetes Res Care. 2022;10(5):e002867. doi:10.1136/bmjdrc-2022-002867
Vasti EC, Basina M, Calma J, Maron DJ, Rodriguez F, Sandhu AT. Disparities in adoption of new diabetic therapies with cardiovascular benefits. Diabetes Res Clin Pract. 2022;196:110233. doi:10.1016/j.diabres.2022.110233
Whyte MB, Hinton W, McGovern A, et al. Disparities in glycaemic control, monitoring, and treatment of type 2 diabetes in England: a retrospective cohort analysis. PLoS Med. 2019;16(10):e1002942. doi:10.1371/journal.pmed.1002942
Morton JI, Ilomӓki J, Magliano DJ, Shaw JE. The association of socioeconomic disadvantage and remoteness with receipt of type 2 diabetes medications in Australia: a nationwide registry study. Diabetologia. 2021;64(2):349-360. doi:10.1007/s00125-020-05304-3
Elhussein A, Anderson A, Bancks MP, et al. Racial/ethnic and socioeconomic disparities in the use of newer diabetes medications in the look AHEAD study. Lancet reg Health Am. 2022;6:100111. doi:10.1016/j.lana.2021.100111
Nicolucci A, Charbonnel B, Gomes MB, et al. Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: results from the global DISCOVER study programme. Diabetes Obes Metab. 2019;21(11):2474-2485. doi:10.1111/dom.13830
Falkentoft AC, Andersen J, Malik ME, et al. Impact of socioeconomic position on initiation of SGLT-2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes - a Danish nationwide observational study. Lancet Reg Health - Europe. 2022;14:100308. doi:10.1016/j.lanepe.2022.100308
Lamprea-Montealegre JA, Madden E, Tummalapalli SL, et al. Association of Race and Ethnicity with Prescription of SGLT2 inhibitors and GLP1 receptor agonists among patients with type 2 diabetes in the veterans health administration system. Jama. 2022;328(9):861-871. doi:10.1001/jama.2022.13885
Pottegård A, Andersen JH, Søndergaard J, Thomsen RW, Vilsbøll T. Changes in the use of glucose-lowering drugs: a Danish nationwide study. Diabetes Obes Metab. 2022;25:1002-1010. doi:10.1111/dom.14947
Bidulka P, Mathur R, Lugo-Palacios DG, et al. Ethnic and socioeconomic disparities in initiation of second-line antidiabetic treatment for people with type 2 diabetes in England: a cross-sectional study. Diabetes Obes Metab. 2023;25(1):282-292. doi:10.1111/dom.14874
Schmidt M, Schmidt SAJ, Adelborg K, et al. The Danish health care system and epidemiological research: from health care contacts to database records. Clin Epidemiol. 2019;11:563-591. doi:10.2147/clep.S179083
Schmidt M, Pedersen L, Sørensen HT. The Danish civil registration system as a tool in epidemiology. Eur J Epidemiol. 2014;29(8):541-549. doi:10.1007/s10654-014-9930-3
Eurostat Glossary: Equivalised disposable income. Available from https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Glossary:Equivalised_disposable_income. Accessed Jan 11 2023
Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449-490. doi:10.2147/clep.S91125
Pottegård A, Schmidt SAJ, Wallach-Kildemoes H, Sørensen HT, Hallas J, Schmidt M. Data resource profile: the Danish National Prescription Registry. Int J Epidemiol. 2017;46(3):798-798f. doi:10.1093/ije/dyw213
Andersen JS, Olivarius Nde F, Krasnik A. The Danish National Health Service Register. Scand J Public Health. 2011;39(7 Suppl):34-37. doi:10.1177/1403494810394718
Isaksen AA, Sandbaek A, Bjerg L. Validation of register-based diabetes classifiers in Danish data. Clin Epidemiol. 2023;15:569-581. doi:10.2147/clep.S407019
Erayil SE, Smith MK, Gebreslasse T, et al. The value and interpretation of race and ethnicity data in the era of global migration: a change is in order. Am J Trop Med Hyg. 2021;105(6):1453-1455. doi:10.4269/ajtmh.21-0665
Singhammer J. Etniske minoriteters sundhed (Health among ethnic minorities). 2008.
Grant RL. Converting an odds ratio to a range of plausible relative risks for better communication of research findings. BMJ: Br Med J. 2014;348:f7450. doi:10.1136/bmj.f7450
Jensen ML, Jorgensen ME, Hansen EH, Aagaard L, Carstensen B. Long-term patterns of adherence to medication therapy among patients with type 2 diabetes mellitus in Denmark: the importance of initiation. PloS One. 2017;12(6):e0179546. doi:10.1371/journal.pone.0179546
Lim L-L, Lau ESH, Cheung JTK, et al. Real-world usage of sulphonylureas in Asian patients with type 2 diabetes using the joint Asia diabetes evaluation (JADE) register. Diabetes Obes Metab. 2023;25(1):208-221. doi:10.1111/dom.14865
Li P, Zhang P, Guan D, et al. Changes in racial and ethnic disparities in glucose-lowering drug utilization and glycated haemoglobin A1c in US adults with diabetes: 2005-2018. Diabetes Obes Metab. 2023;25(2):516-525. doi:10.1111/dom.14894
Dor A, Encinosa W. How does cost-sharing affect drug purchases? Insurance regimes in the private market for prescription drugs. National Bureau of Economic Research Working Paper Series No. 10738. 2004. doi:10.3386/w10738
McManus P, Donnelly N, Henry D, Hall W, Primrose J, Lindner J. Prescription drug utilization following patient co-payment changes in Australia. Pharmacoepidemiol Drug Saf. 1996;5(6):385-392. doi:10.1002/(sici)1099-1557(199611)5:6<385::Aid-pds246>3.0.Co;2-8
Khan H, Lasker SS, Chowdhury TA. Prevalence and reasons for insulin refusal in Bangladeshi patients with poorly controlled type 2 diabetes in East London. Diabetic Med: J Br Diabetic Assoc. 2008;25(9):1108-1111. doi:10.1111/j.1464-5491.2008.02538.x
Hu J, Amirehsani KA, Wallace DC, Letvak S. The meaning of insulin to Hispanic immigrants with type 2 diabetes and their families. Diabetes Educ. 2012;38(2):263-270. doi:10.1177/0145721712437559
Mull DS, Nguyen N, Mull JD. Vietnamese diabetic patients and their physicians: what ethnography can teach us. West J Med. 2001;175(5):307-311. doi:10.1136/ewjm.175.5.307
Dowle M, Srinivasan A. data.table: Extension of ‘data.frame’. 2023. https://r-datatable.com
R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; 2023. https://www.R-project.org/
RStudio Team. RStudio: Integrated Development Environment for R. RStudio, PBC; 2022. http://www.rstudio.com/